Ulcerative colitis is a chronic, immune-mediated disorder of the colon, which is characterised by a relapsing–remitting course. Owing to the growing understanding of the immunopathogenesis of this ...

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient ...

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved ...

Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled "Antibody?Gamma/Delta T ...

Using a single-cell RNA-sequencing platform, a new study demonstrates that EBV reprograms autoreactive B cells to drive lupus autoimmunity.

Barr virus transforms B cells into inflammatory drivers that spark the widespread immune attacks seen in lupus.

One of humanity's most ubiquitous infectious pathogens bears the blame for the chronic autoimmune condition called systemic ...

Early immune activation marks the onset of rheumatoid arthritis, revealing potential for early intervention and improved ...

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.